A clinical trial assessing EB1010 in patients with inflammatory bowel disease
Latest Information Update: 15 Mar 2023
At a glance
- Drugs EB 1010 Enterome (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions
- Sponsors Enterome
- 10 Mar 2023 According to Enterome media release, this trial is expects to initiate in 2024.
- 18 Jul 2022 According to Enterome media release, EB1010 is being developed in collaboration with Nestle Health Science.
- 18 Nov 2021 New trial record